Ownership and insider activity for Nkarta, Inc. (NKTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as w...
Price
| Price | $2.87 |
| Market Cap | $205M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $20.6M | $96.7M | $60.8M | $37.5M | $31.0M | $27.9M | $39.6M |
| Short-term Investments | 0 | $16.4M | $218.2M | $177.3M | $314.6M | $217.1M | $239.5M | $236.6M |
| Receivables | $150000 | 0 | 0 | 0 | $1.3M | $200000 | $200000 | $2.0M |
| Inventory | $117290 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $8.2M | $37.5M | $318.8M | $245.8M | $360.7M | $253.1M | $273.3M | $282.5M |
| Property, Plant & Equipment | $1.3M | $10.2M | $17.9M | $24.5M | $107.7M | $119.3M | $110.7M | $101.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $9.6M | $48.4M | $337.6M | $273.9M | $472.9M | $378.9M | $501.2M | $404.2M |
| Accounts Payable | $367172 | $1.9M | $1.2M | $1.1M | $1.8M | $3.7M | $638000 | $2.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | $4.2M | 0 | 0 | 0 |
| Total Current Liabilities | $2.1M | $8.2M | $8.8M | $12.9M | $22.0M | $23.3M | $18.9M | $22.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $15.0M | $73.9M | $16.4M | $22.9M | $100.7M | $105.6M | $93.2M | $91.9M |
| Retained Earnings | -$5.6M | -$26.7M | -$118.0M | -$204.1M | -$317.9M | -$435.4M | -$544.2M | -$648.3M |
| Total Equity | -$5.4M | -$25.5M | $321.2M | $251.0M | $372.2M | $273.3M | $408.0M | $312.3M |
| Total Debt | $12.7M | $7.3M | $8.9M | $12.5M | $82.9M | $88.3M | $80.3M | $76.4M |
| Net Debt | $4.8M | -$29.7M | -$306.0M | -$225.6M | -$269.2M | -$159.8M | -$187.1M | -$199.9M |
| Working Capital | $6.2M | $29.3M | $310.0M | $232.8M | $338.6M | $229.7M | $254.4M | $260.2M |
Financial Health
| Debt / Equity | 0.30 |
| Current Ratio | 7.98 |
Profitability
| Return on Equity | -39.64% |
| Return on Invested Capital | -41.15% |
| Return on Assets | -34.75% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CYBN · ELTX · FATE · FBRX · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NKTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks